Inflammatory breast cancer in a 53-year-old man

Document Type : CASE REPORT

Authors
Hassan Moayeri 1
Payman Rezagholi 2
1 Department of Surgery, School of Medicine, Kowsar Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran
2 Department of Operating Room, Faculty of Nursing and Midwifery, Kurdistan University of Medical Sciences, Sanandaj, Iran
Abstract
Diagnosing breast cancer (BC) in early stages increases the chances of treating this cancer in men. However, because BC is very rare in men, especially inflammatory BC (IBC), it is unlikely that screening men for BC by mammography or other tests would yield promising outcomes. The aim of this study was to report IBC in a 53-year-old man. The case was a 53-year-old man with a history of mass in the left breast and trauma to the same side as well as swelling and severe redness of the breast skin. The patient underwent neoadjuvant chemotherapy and relative responded to medical treatment. He then underwent modified mastectomy surgery and initial chest wall repair followed by radiotherapy. IBC in men is challenging due to its rarity, unknown biological behaviors, and difficulty in early diagnosis. This tumor is usually detected in advanced stages in the elderly and has a poor prognosis.

Keywords

1.
Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: Summary and research recommendations. J Clin Oncol 2010;28:2114-22.  Back to cited text no. 1
    
2.
Burga AM, Fadare O, Lininger RA, Tavassoli FA. Invasive carcinomas of the male breast: A morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch 2006;449:507-12.  Back to cited text no. 2
    
3.
Darkeh MH, Azavedo E. Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches. Int J Clin Med 2014;5:1068-86.  Back to cited text no. 3
    
4.
Key Statistics for Breast Cancer in Men. Available from: https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html. [Last accessed on 2018 Mar 05].  Back to cited text no. 4
    
5.
How common is Breast Cancer? Available form: https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html. [Last accessed on 2018 Mar 05].  Back to cited text no. 5
    
6.
Surveillance Research Program NCI. SEER* Explorer: An interactive website for SEER cancer statistics.  Back to cited text no. 6
    
7.
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER Cancer Statistics Review, 1975–2014. Bethesda, MD: National Cancer Institute; 2017.  Back to cited text no. 7
    
8.
Giotta F, Acito L, Candeloro G, Del Medico P, Gadaleta-Caldarola G, Giordano G, et al. Eribulin in male patients with breast cancer: The first report of clinical outcomes. Oncologist 2016;21:1298-305.  Back to cited text no. 8
    
9.
Cardoso F, Bartlett JM, Slaets L, Van Deurzen CH, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncology 2018;29:405-17.  Back to cited text no. 9
    
10.
Cardoso F, Bartlett JM, Slaets L, van Deurzen CH, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program. Ann Oncol 2018;29:405-17.  Back to cited text no. 10
    
11.
Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Annals of oncology. 2013;24:1434-43.  Back to cited text no. 11
    
12.
Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother 2007;8:193-202.  Back to cited text no. 12
    
13.
Mills GC, Alperin JB, Trimmer KB. Studies on variant glucose-6-phosphate dehydrogenases: G6PD Fort Worth. Biochem Med 1975;13:264-75.  Back to cited text no. 13
    
14.
Lautrup MD, Thorup SS, Jensen V, Bokmand S, Haugaard K, Hoejris I, et al. Male breast cancer: A nation-wide population-based comparison with female breast cancer. Acta Oncol 2018;57:613-21.  Back to cited text no. 14
    
15.
Weir J, Zhao YD, Herman T, Algan Ö. Clinicopathologic features and radiation therapy utilization in patients with male breast cancer: A national cancer database study. Breast Cancer (Auckl) 2018;12:1-7.  Back to cited text no. 15
    
16.
Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, et al. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012;25:398-404.  Back to cited text no. 16
    
17.
Perez CA, Fields JN, Fracasso PM, Philpott G, Soares RL Jr., Taylor ME, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer 1994;74 Suppl 1:466-76.  Back to cited text no. 17
    
18.
Borgen PI, Woung GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, et al. Current management of male breast cancer. A review of 104 cases. Ann Surg 1992;215:451-7.  Back to cited text no. 18
    
19.
Morita Y, Syoji T, Goto H, Nakajima T, Hukasawa T, Taniwaka K. A case report of male inflammatory breast cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 2005;66:36-40.  Back to cited text no. 19
    
20.
Sutherland S, Ashley S, Walsh G, Smith IE, Johnston SR. Inflammatory breast cancer—The Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007. Cancer 2010;116:2815-20.  Back to cited text no. 20
    
Advanced Biomedical Research
Volume 2022, January
January 2022
Pages 1-5